A first principle study on the interaction between acetylcholinesterase and acetylcholine, and also rivastigmine in Alzheimer's disease case

3Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The catalytic activity of acetylcholinesterase enzyme (AChE) relates to the symptom progress in Alzheimer's disease. Interaction of AChE with rivastigmine (from the medicine) can reduce its catalytic activity toward acetylcholine to decelerate the progression of Alzheimer's disease. This research attempts to study the interaction between AChE and rivastigmine, and also acetylcholine (without the presence of rivastigmine) using density functional theory by simplifying the reaction occurs in the active site, which is assumed to be C2H5OH, C3N2H3(Ch3), and CH3COO-. The results suggest that AChE interacts easier with acetylcholine than with rivastigmine, which implies that the medicine does not effectively reduce the catalytic activity of AChE. At this stage, no experimental data is available to be compared with the calculation results. Nonetheless, this study has shown a good prospect to understand the AChE-substrate interaction using a first-principles calculation.

Cite

CITATION STYLE

APA

Khoirunisa, V., Rusydi, F., Kasai, H., Gandaryus, A. G., & Dipojono, H. K. (2016). A first principle study on the interaction between acetylcholinesterase and acetylcholine, and also rivastigmine in Alzheimer’s disease case. In Journal of Physics: Conference Series (Vol. 739). Institute of Physics Publishing. https://doi.org/10.1088/1742-6596/739/1/012136

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free